Comparable stake leader
TPG GP A, LLC
SEC ownership of ACHIEVE LIFE SCIENCES, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000949858.
Disclosed value leader
Logos Global Management LP
Comparable rows
50/50
Latest evidence
06 Jul 2026
- Public ticker
- ACHV on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
TPG GP A, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
TPG GP A, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
06 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000949858
- Issuer location
- Seattle, WA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ACHIEVE LIFE SCIENCES, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TPG GP A, LLC
Disclosed value leader
Logos Global Management LP
Comparable rows
50/50
Latest evidence
06 Jul 2026
13F
13D/G
3/4/5
Lead comparable stake: 13%
13D/G row: TPG GP A, LLC
Showing 1-8 of 50 holder rows.
Quick read
TPG GP A, LLC leads the comparable SEC ownership view at 13%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TPG GP A, LLC's linked filing trail.
Comparable ownership
Top 5
TPG GP A, LLC
13%
Logos Global Management LP
10%
venBio Global Strategic Fund V, L.P.
10%
Paradigm Biocapital Advisors LP
9.2%
FRANKLIN RESOURCES INC
8.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TPG GP A, LLC |
13F
13D/G
3/4/5
Company · 10%+ Owner
|
13%
from 13D/G
|
$44,910,597
6,877,580 shares
|
— | 30 Jun 2026 |
| Logos Global Management LP |
13D/G
13F
Company
|
10%
|
$64,284,484
10,538,440 shares
|
$0 | 11 May 2026 |
| venBio Global Strategic Fund V, L.P. |
13D/G
|
10%
|
$31,567,712
10,737,317 shares
|
$0 | 15 Apr 2026 |
| Paradigm Biocapital Advisors LP |
13F
13D/G
Company
|
9.2%
from 13D/G
|
$32,335,620
4,951,856 shares
|
— | 30 Jun 2026 |
| FRANKLIN RESOURCES INC |
13D/G
13F
Company
|
8.3%
|
$57,979,491
8,878,942 shares
|
+$16,388,276 | 30 Jun 2026 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
6.5%
|
$19,479,817
6,625,788 shares
|
$0 | 17 Apr 2026 |
| Alyeska Investment Group, L.P. |
13F
13D/G
Company
|
5.6%
from 13D/G
|
$12,574,965
1,925,722 shares
|
— | 30 Jun 2026 |
| Janus Henderson Group Ltd. |
13D/G
|
5.4%
|
$33,562,590
5,502,064 shares
|
$0 | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$175,177.
Buys
$0
Insiders: 0
Sells
$175,177
Insiders: 1
Net
-$175,177
Shares: -20,626
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 20,626
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 20,626 | $0 | $175,177 | -$175,177 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 31 reporting-owner rows connected to ACHIEVE LIFE SCIENCES, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
31
Largest Forms 3/4/5 holder
Jon Winkelried
Net 12M change
-$175,177
Latest report
19 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jon Winkelried | 10%+ Owner | $20,220,085 | Mixed | 17 Apr 2026 | ||
| James G. Coulter | 10%+ Owner | $20,220,085 | Mixed | 17 Apr 2026 | ||
| TPG GP A, LLC | 10%+ Owner | $20,220,085 | Mixed | 17 Apr 2026 | ||
| DIALECTIC CAPITAL MANAGEMENT, LP | 10%+ Owner | $19,519,500 | Mixed | 18 Nov 2022 | ||
| Thomas B. King | Director | $2,542,793 | Mixed | 04 Sep 2025 | ||
| Richard Alistair Stewart | Director | $2,354,786 | -$175,177 | -6.9% | Mixed | 19 Aug 2026 |
| Mark K. Oki | Chief Financial Officer | $990,144 | Mixed | 18 Sep 2025 | ||
| Cindy Jacobs | President & CMO | $797,270 | Mixed | 04 Sep 2025 | ||
| Jaime Xinos | Chief Commercial Officer | $573,176 | Mixed | 04 Sep 2025 | ||
| John Bencich | CEO, Director | $369,334 | Mixed | 16 Aug 2024 | ||
| Jerry Wan | Principal Accounting Officer | $266,722 | Mixed | 04 Sep 2025 | ||
| Mark Lawrence Rubinstein | Chief Medical Officer | $185,724 | Mixed | 01 Jan 2026 | ||
| Craig Donnelly | Chief Operations Officer | $165,495 | Mixed | 01 Oct 2025 | ||
| Anthony Clarke | Cso | $39,490 | Mixed | 28 Apr 2022 | ||
| Vaughn B. Himes | Director | Mixed | 22 Jan 2024 | |||
| Erik Atkisson | Chief Legal Officer | Mixed | 04 Dec 2025 | |||
| Andrew D. Goldberg | CEO and President, Director | Mixed | 18 Apr 2026 | |||
| Lucian Iancovici | Director | Mixed | 17 Apr 2026 | |||
| Kristen B. Slaoui | Director | Mixed | 06 Jun 2025 | |||
| Nancy R. Phelan | Director | Mixed | 27 Jul 2026 |
Recent insider transactions for ACHIEVE LIFE SCIENCES, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Richard Alistair Stewart | ACHV | Common Stock | Sale | -9.01% | $175,177 | $8.49 | -20,626 | 208,249 | 19 Aug 2026 | Direct |
| Thomas Sellig | ACHV | Restricted Stock Unit (RSU) | Award | 16,700 | 16,700 | 27 Jul 2026 | Direct | |||
| Thomas Sellig | ACHV | Stock Option (right to buy) | Award | 25,000 | 25,000 | 27 Jul 2026 | Direct | |||
| Christopher Nathan Martin | ACHV | Restricted Stock Unit (RSU) | Award | 16,700 | 16,700 | 27 Jul 2026 | Direct | |||
| Christopher Nathan Martin | ACHV | Stock Option (right to buy) | Award | 25,000 | 25,000 | 27 Jul 2026 | Direct | |||
| Aaron Royston | ACHV | Restricted Stock Unit (RSU) | Award | 16,700 | 16,700 | 27 Jul 2026 | Direct | |||
| Aaron Royston | ACHV | Stock Option (right to buy) | Award | 25,000 | 25,000 | 27 Jul 2026 | Direct | |||
| Reid Alexander Waldman | ACHV | Restricted Stock Unit (RSU) | Award | 16,700 | 16,700 | 27 Jul 2026 | Direct | |||
| Reid Alexander Waldman | ACHV | Stock Option (right to buy) | Award | 25,000 | 25,000 | 27 Jul 2026 | Direct | |||
| Richard Alistair Stewart | ACHV | Restricted Stock Unit (RSU) | Award | 16,700 | 16,700 | 27 Jul 2026 | Direct | |||
| Richard Alistair Stewart | ACHV | Stock Option (right to buy) | Award | 25,000 | 25,000 | 27 Jul 2026 | Direct | |||
| Jeffrey S. Farrow | ACHV | Restricted Stock Unit (RSU) | Award | 16,700 | 16,700 | 27 Jul 2026 | Direct | |||
| Jeffrey S. Farrow | ACHV | Stock Option (right to buy) | Award | 25,000 | 25,000 | 27 Jul 2026 | Direct | |||
| Nancy R. Phelan | ACHV | Restricted Stock Unit (RSU) | Award | 16,700 | 16,700 | 27 Jul 2026 | Direct | |||
| Nancy R. Phelan | ACHV | Stock Option (right to buy) | Award | 25,000 | 25,000 | 27 Jul 2026 | Direct | |||
| Reid Alexander Waldman | ACHV | Stock Option (right to buy) | Award | 47,250 | 47,250 | 29 May 2026 | Direct | |||
| Jeffrey S. Farrow | ACHV | Stock Option (right to buy) | Award | 47,250 | 47,250 | 29 May 2026 | Direct | |||
| Christopher Nathan Martin | ACHV | Stock Option (right to buy) | Award | 47,250 | 47,250 | 11 May 2026 | Direct | |||
| Andrew D. Goldberg | ACHV | Performance Restricted Stock Unit (PRSU) | Award | 11,706,270 | 11,706,270 | 18 Apr 2026 | Direct | |||
| Andrew D. Goldberg | ACHV | Stock Option (right to buy) | Award | 3,601,929 | 3,601,929 | 18 Apr 2026 | Direct | |||
| Andrew D. Goldberg | ACHV | Restricted Stock Unit (RSU) | Award | 1,800,965 | 1,800,965 | 18 Apr 2026 | Direct | |||
| Mark Lawrence Rubinstein | ACHV | Stock Option (right to buy) | Award | 180,000 | 180,000 | 28 Jan 2026 | Direct | |||
| Craig Donnelly | ACHV | Stock Option (right to buy) | Award | 180,000 | 180,000 | 28 Jan 2026 | Direct | |||
| Jaime Xinos | ACHV | Stock Option (right to buy) | Award | 180,000 | 180,000 | 28 Jan 2026 | Direct | |||
| Jerry Wan | ACHV | Stock Option (right to buy) | Award | 70,300 | 70,300 | 28 Jan 2026 | Direct | |||
| Richard Alistair Stewart | ACHV | Stock Option (right to buy) | Award | 645,000 | 645,000 | 28 Jan 2026 | Direct | |||
| Mark K. Oki | ACHV | Stock Option (right to buy) | Award | 180,000 | 180,000 | 28 Jan 2026 | Direct | |||
| Erik Atkisson | ACHV | Stock Option (right to buy) | Award | 250,000 | 250,000 | 04 Dec 2025 | Direct | |||
| Craig Donnelly | ACHV | Stock Option (right to buy) | Award | 50,000 | 50,000 | 01 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.